Healthcare
Dermapharm Holding SE(DMPHF)
Live Price
Offline$53.00
+33.97% today
1Y Change
+33.97%
Window
Jun 25, 2025 β Jun 22, 2026
- Market Cap
- $2.51B
- Revenue Growth
- -1.4%
- EPS Growth
- +16.6%
- Dividend Yield
- 1.9%
Coverage: 254 bars Β· Jun 25, 2025 β Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dermapharm Holding SE (DMPHF) is a Healthcare stock with a market cap of $2.51B and listed on OTC. The stock last traded around $53.00 and up 34.0% across the available one-year price window (Jun 25, 2025 β Jun 22, 2026). Baseline metrics include revenue growth of -1.4%, EPS growth of +16.6%, a dividend yield of 1.9%. What stands out right now is revenue -1.4%, EPS +16.6%, free cash flow -14.6% with operating margin 19.1% and ROIC 8.0%. The dividend is present but secondary, with a yield around 1.9%. Valuation is more restrained than many high-expectation growth names at P/E 19.0 and price/sales 2.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DMPHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.4% vs +7.6% peer median
Operating Margin
Near sector median
+19.1% vs +19.4% peer median
P/E
Below sector median
19.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.4% and EPS is at +16.6%, with operating margin around 19.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | β | +0.0% | +0.0% | +0.0% |
2026 Mar 10, 2026 | +68.2% | +0.0% | +0.0% | +0.0% |
2025 Aug 26, 2025 | β | +0.0% | +0.0% | +0.0% |
Benchmark Edge
DMPHF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DMPHF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DMPHF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DMPHF and SPY.
Company Overview
Dermapharm Holding SE
Other OTC
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in GrΓΌnwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
- Leadership
- Hans-Georg Feldmeier
- IPO Date
- Nov 29, 2022
- Employees
- 3.6k
- Street Address
- Lil-Dagover-Ring 7
- Mailing
- GrΓΌnwald, 82031
- Region
- GrΓΌnwald, DE
- Reporting Currency
- USD
- Investor Line
- 49 89 6 41 86 0
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.0
- EV/EBITDA
- 10.4
- Price/Sales
- 2.2
- Price/Book
- 3.6
Growth
- Revenue
- -1.4%
- EPS
- +16.6%
- Free Cash Flow
- -14.6%
Profitability
- Gross Margin
- 50.6%
- Operating Margin
- 19.1%
- Net Margin
- 11.4%
- ROE
- 20.4%
- ROIC
- 8.0%
Balance Sheet
- Debt/Equity
- 1.52
- Current Ratio
- 2.05
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.